Trial record 9 of 20 for:
" April 04, 2007":" May 04, 2007"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
A Pharmacokinetic Study of Dapivirine Vaginal Rings in Belgium
This study has been completed.
Sponsor:
International Partnership for Microbicides, Inc.
Information provided by:
International Partnership for Microbicides, Inc.
ClinicalTrials.gov Identifier:
NCT00469768
First received: May 3, 2007
Last updated: August 31, 2009
Last verified: August 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
IPM 018 is a double-blind, randomized, placebo-controlled study conducted at one site in Belgium among 24 healthy, HIV-negative women to evaluate dapivirine release for 28 days from matrix and reservoir intravaginal rings, each containing 25 mg of dapivirine, and to assess safety and tolerability compared to placebo
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections |
Drug: dapivirine reservoir intravaginal ring Drug: dapivirine matrix intravaginal ring Other: placebo intravaginal ring |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention |
| Official Title: | A Double-blind, Randomized, Placebo-controlled Safety and Pharmacokinetic Study in Healthy HIV-negative Women to Assess the Delivery of Dapivirine From Matrix and Reservoir Intravaginal Rings Each Containing 25 mg of Dapivirine |
Resource links provided by NLM:
Genetics Home Reference related topics:
complement factor I deficiency
MedlinePlus related topics:
HIV/AIDS
U.S. FDA Resources
Further study details as provided by International Partnership for Microbicides, Inc.:
| Enrollment: | 24 |
| Study Start Date: | May 2007 |
| Study Completion Date: | August 2007 |
| Arms | Assigned Interventions |
|---|---|
| Experimental: A |
Drug: dapivirine matrix intravaginal ring
a silicone elastomer matrix intravaginal ring containing 25mg of dapivirine
|
| Experimental: B |
Drug: dapivirine reservoir intravaginal ring
a silicone elastomer reservoir ring containing 25mg of dapivirine
|
| Placebo Comparator: C |
Other: placebo intravaginal ring
a silicone elastomer intravaginal ring containing no dapivirine
|
Eligibility| Ages Eligible for Study: | 18 Years to 35 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Women between 18 and 35 years of age
- Willing and able to give written informed consent
- Available for all visits and consent to follow all procedures scheduled for the study
- Healthy and HIV-negative as determined by a HIV-1 ELISA test at time of enrollment;
- Willing to abstain from sexual activity for the duration of the study
- Willing to use oral contraceptives to avoid menstruation while taking part in this study or on long-acting progestins for 6 months prior to enrollment
- Upon pelvic / speculum examination at enrollment, the cervix and vagina appear normal
- Willing to refrain from use of vaginal products or objects for the duration of the study.
Exclusion Criteria:
- History of alcoholism, drug abuse, psychosis, antagonistic personality, poor motivation, or other emotional or intellectual problems that are likely to invalidate the informed consent process or adversely impact compliance with protocol requirements;
- History of sensitivity / allergy to latex, dapivirine or to the constituents of the vaginal ring (i.e. silicone elastomer)
- Currently pregnant or breast-feeding, or within three months of last pregnancy outcome
- Currently or within one month of participating in any other clinical research study
- History or diagnosis of and / or treatment for a sexually transmitted disease within the last three months
- History of genital tract surgery within the last month
- Current diagnosis of sexually transmitted infections (Gonorrhea, Chlamydia and Trichomonas)
- Current vulvar or vaginal symptoms / abnormalities that could influence the study results
- History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding or urethral obstruction within the last three months;
- Smoking more than 10 cigarettes per day
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00469768
Locations
| Belgium | |
| Drug Research Unit Ghent (D.R.U.G.) | |
| Ghent, Belgium, 9000 | |
Sponsors and Collaborators
International Partnership for Microbicides, Inc.
Investigators
| Study Director: | Dr. Annalene Nel | International Partnership for Microbicides (IPM) |
More Information
Additional Information:
No publications provided
| Responsible Party: | Zeda Rosenberg ScD, International Partnership for Microbicides |
| ClinicalTrials.gov Identifier: | NCT00469768 History of Changes |
| Other Study ID Numbers: | IPM 018 |
| Study First Received: | May 3, 2007 |
| Last Updated: | August 31, 2009 |
| Health Authority: | Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment |
Keywords provided by International Partnership for Microbicides, Inc.:
|
HIV-1 infection HIV Seronegativity |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on June 18, 2013